Expanded Access to Ensartinib for Participants With ALK+ NSCLC
NCT04146571
·
clinicaltrials.gov ↗
AVAILABLE
Status
INDUSTRY
Sponsor class
Conditions
Non-Small Cell Lung Cancer
ALK Gene Rearrangement Positive
Interventions
DRUG:
Ensartinib
Sponsor
Xcovery Holdings, Inc.